Co-administration of a lysostaphin or other anti-staphylococcal agent
which cleaves cross-links of peptidoglycans of staphylococci cell walls
such as lysostaphin and an antibiotic effective against staphylococci due
to antibiotic activity mediated by cell-wall activity is effective
against staphylococcal infection, even staphylococci that may be
resistant to one or other of lysostaphin or the cell-wall active
antibiotic. Co-administration simultaneously suppresses the generation of
antibiotic-resistant mutant strains. Effective cell-wall active
antibiotics include .beta.-lactams and glycopeptides.